Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
61
EYPT Quote, Financials, Valuation and Earnings
Last price:
$17.50
Seasonality move
:
6.32%
Day range:
$17.74 - $18.34
52-week range:
$3.91 - $19.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
29.60x
P/B ratio:
7.56x
Volume:
624K
Avg. volume:
1.2M
1-year change:
145.23%
Market cap:
$1.5B
Revenue:
$43.3M
EPS (TTM):
-$2.99
Analysts' Opinion
-
Consensus RatingEyePoint Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $36.08, EyePoint Plc has an estimated upside of 97.5% from its current price of $18.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $18.27.
Fair Value
-
According to the consensus of 10 analysts, EyePoint Plc has 97.5% upside to fair value with a price target of $36.08 per share.
EYPT vs. S&P 500
-
Over the past 5 trading days, EyePoint Plc has overperformed the S&P 500 by 0.63% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
EyePoint Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
EyePoint Plc revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter EyePoint Plc reported revenues of $966K.
Earnings Growth
-
EyePoint Plc earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter EyePoint Plc reported earnings per share of -$0.85.
Enterprise value:
1.3B
EV / Invested capital:
--
Price / LTM sales:
29.60x
EV / EBIT:
--
EV / Revenue:
31.45x
PEG ratio (5yr expected):
-0.12x
EV / Free cash flow:
-6.24x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$39.3M
Return On Assets:
-62.93%
Net Income Margin (TTM):
-485.95%
Return On Equity:
-79.15%
Return On Invested Capital:
-72.69%
Operating Margin:
-6420.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $42.5M | $45.7M | $42.3M | $10.5M | $966K | |
| Gross Profit | $35.3M | $41.8M | $39.3M | $9.8M | $245K | |
| Operating Income | -$81.7M | -$117M | -$218.3M | -$32.7M | -$62M | |
| EBITDA | -$81.1M | -$115.8M | -$216.3M | -$32.3M | -$61.4M | |
| Diluted EPS | -$2.67 | -$2.01 | -$2.99 | -$0.54 | -$0.85 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $141.8M | $192.1M | $150.2M | $268.5M | $216.1M | |
| Total Assets | $168.3M | $220.5M | $160M | $300.9M | $251.7M | |
| Current Liabilities | $19.9M | $34.3M | $63.9M | $48.8M | $30.1M | |
| Total Liabilities | $75.5M | $84.1M | $101.4M | $82.2M | $51.5M | |
| Total Equity | $92.7M | $136.4M | $58.6M | $218.7M | $200.2M | |
| Total Debt | $38.6M | $35.6M | $5.2M | $21.9M | $21.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $12.4M | -$113.5M | -$210.9M | -$39M | -$59.4M | |
| Cash From Investing | $76.8M | -$170.5M | $47.3M | $16.2M | $55.4M | |
| Cash From Financing | -$31.5M | $230.8M | $158.4M | $11.9M | $7.4M | |
| Free Cash Flow | $9.2M | -$118M | -$213.6M | -$40.6M | -$60.2M | |
EYPT
Sector
Market Cap
$1.5B
$28.1M
Price % of 52-Week High
95.6%
50%
Dividend Yield
0%
0%
Shareholder Yield
-16.2%
-1.54%
1-Year Price Total Return
145.24%
-17.67%
Beta (5-Year)
1.630
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$18.20
200-day SMA
Buy
Level
$10.66
Bollinger Bands (100)
Buy
Level
11.41 - 15.75
Chaikin Money Flow
Sell
Level
-205.4M
20-day SMA
Buy
Level
$17.27
Relative Strength Index (RSI14)
Buy
Level
64.74
ADX Line
Buy
Level
33.77
Williams %R
Neutral
Level
-22.884
50-day SMA
Buy
Level
$14.50
MACD (12, 26)
Buy
Level
1.06
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
137.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.714)
Sell
CA Score
(Annual)
Level (-0.8398)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (1.4989)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Stock Forecast FAQ
In the current month, EYPT has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EYPT average analyst price target in the past 3 months is $36.08.
-
Where Will EyePoint Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that EyePoint Plc share price will rise to $36.08 per share over the next 12 months.
-
What Do Analysts Say About EyePoint Plc?
Analysts are divided on their view about EyePoint Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that EyePoint Plc is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is EyePoint Plc's Price Target?
The price target for EyePoint Plc over the next 1-year time period is forecast to be $36.08 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EYPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for EyePoint Plc is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EYPT?
You can purchase shares of EyePoint Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase EyePoint Plc shares.
-
What Is The EyePoint Plc Share Price Today?
EyePoint Plc was last trading at $17.50 per share. This represents the most recent stock quote for EyePoint Plc. Yesterday, EyePoint Plc closed at $18.27 per share.
-
How To Buy EyePoint Plc Stock Online?
In order to purchase EyePoint Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get EYPT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EYPT
Sector
P/E ratio
--
23.88x
PEG ratio
-0.12x
-0.01x
P/B ratio
7.56x
1.82x
Price / LTM sales
29.60x
1.59x
Growth Metrics
EYPT
Sector
Revenue growth
-90.82%
4.73%
Earnings growth
-57.88%
11.11%
Revenue (5-year growth)
16.27%
6.46%
Earnings forecast
-$0.75
-$0.18
Profitability
EYPT
Sector
Profitability FY 2024
$39.6M
$3.6M
Return on invested capital
-72.69%
-31.77%
Return on assets
-62.93%
-28.18%
Return on equity
-79.15%
-37.47%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
4
Estimated Next Earnings Date
Feb
4
Balance Sheet
EYPT
Sector
Total cash
$204M
$26.3M
Short term investments
$271.2M
$26M
Total assets
$418.5M
$76.9M
Long term debt
$21.3M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 6.12% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.13% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 7.67% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
